Search
for
Sort by
Research 181–210 of 1000+
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- Quoi de neuf en dermatologie pédiatrique ?
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- Under Development JAK Inhibitors for Dermatologic Diseases
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- Spotlight in Plastic Surgery: October 2022
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Current Treatments for Alopecia Areata
- Medical Therapies
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Alopecia Areata
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Alopecia Areata: An Updated Review for 2023
- Alopecia areata